Cellular Metabolism

NAD+ intravenous therapy

A slow intravenous infusion of nicotinamide adenine dinucleotide (NAD+), the coenzyme every cell uses to make energy and repair DNA, given on our ward over 2–4 hours as one module of a plan for chronic fatigue, Post-COVID, Lyme disease and age-related decline. The evidence is emerging; human trial data for the infusion itself are sparse.

Conceptual illustration of paired glass discs and a teal token representing a cofactor.
What it is

What NAD+ infusion is

St. George Hospital gives NAD+ (nicotinamide adenine dinucleotide) as a slow intravenous infusion over two to four hours, on the ward, as one module of a plan for chronic fatigue, Post-COVID, Lyme disease and age-related decline. It belongs to our infusion and immune therapies and is prescribed from the work-up, never as a course on its own. Outside the licensed use of its precursors it is an individual treatment attempt decided with the patient after medical consultation.

NAD+ is a coenzyme present in every living cell. It carries electrons in the mitochondrial chain that produces ATP, it is the substrate for the sirtuin enzymes involved in DNA repair and gene regulation, and for the PARP enzymes that repair DNA damage, and it is consumed by CD38 in inflammatory signaling. Tissue levels fall with age and are lowered further by chronic illness, infection and metabolic stress, which is why the molecule interests physicians who treat fatigue.

What the infusion does in the blood is documented. In a pilot study of a six-hour NAD+ infusion at 3 µmol per minute, plasma NAD+ and its metabolites did not rise at all during the first two hours, meaning the molecule was taken up or broken down as fast as it arrived, and by the sixth hour NAD+ and methylnicotinamide appeared in the urine (Grant et al., Front Aging Neurosci, 2019). That study describes the pharmacology; it did not measure symptoms. The claim that intravenous dosing reaches levels oral intake cannot is plausible from that pharmacology, and it remains unproven in an outcome trial. A longer explanation of NAD+ and aging is in our article on NAD+, age-related decline and supplementation.

Diagram of the NAD salvage pathway: nicotinamide is converted by NAMPT to NMN and by NMNAT to NAD+
The NAD+ salvage pathway. Schematic, not to scale.
Who it is for

Which conditions it is used for

Our physicians consider NAD+ infusions where the work-up shows impaired energy metabolism and the main complaint is exhaustion that does not recover with rest. The decision follows your findings.

  • Chronic fatigue and ME/CFS with mitochondrial dysfunction in the metabolic work-up
  • Post-COVID with persistent fatigue and post-exertional malaise
  • Chronic Lyme disease, during and after antimicrobial therapy, when fatigue is the dominant symptom
  • Age-related metabolic decline assessed in the longevity program
  • Neurodegenerative conditions, as supportive care alongside the neurologist's treatment
  • Recovery after a long illness or surgery, where the laboratory shows depleted reserves

We do not give NAD+ infusions in pregnancy or while breastfeeding, in unstable heart disease or uncontrolled high blood pressure, or during active chemotherapy without the agreement of our oncology team, because the metabolic effects in tumor tissue are not well characterized. In kidney impairment the rate is reduced. A history of severe reactions to niacin is discussed with the physician before the first dose.

In the room

How a session runs on our ward

  1. Before the first session, on the first or second day of your stay, the laboratory includes kidney values, a blood count and the metabolic markers of the work-up. You fill in the fatigue questionnaire that will be repeated in the second week.
  2. A nurse places a peripheral IV line in the treatment chair and records pulse and blood pressure. The drip starts deliberately slowly.
  3. Over the first 30 to 60 minutes the rate is raised step by step as you tolerate it. If you feel chest tightness, nausea, flushing or muscle cramping, say so at once; the nurse slows the drip and the symptom usually settles within minutes. Most patients then feel little beyond a mild warmth.
  4. The infusion runs two to four hours in total. You can read, rest or talk; a nurse checks on you throughout, and the physician is on the ward.
  5. Afterwards you walk back to your room and continue your day. Sessions are spaced across the stay, usually three to five in two to three weeks, and never on the same day as another long infusion.

Evidence and safety, graded

The evidence is emerging, and most of it comes from oral precursors rather than the infusion. Side effects such as chest tightness or nausea depend on the drip rate and settle when it is slowed.

Show studies, risks and side effects

The evidence for NAD+ therapy is emerging, and most of it comes from oral precursors rather than the infusion. In a randomized, placebo-controlled trial in healthy middle-aged and older adults, six weeks of oral nicotinamide riboside raised blood NAD+ and was well tolerated (Martens et al., Nat Commun, 2018). A systematic review of ten randomized trials with 489 participants, covering chronic fatigue syndrome, prediabetes and Alzheimer's disease, found NADH and precursor supplementation well tolerated, with measured effects on fatigue intensity, sleep and maximum heart rate after exercise in the fatigue trials (Gindri et al., Am J Physiol Endocrinol Metab, 2024).

The closest trial to our patients is an eight-week randomized, double-blind study of oral coenzyme Q10 plus NADH in 80 patients with chronic fatigue syndrome: maximum heart rate on a cycle ergometer fell and perceived fatigue decreased against placebo, while pain and sleep did not change (Castro-Marrero et al., Clin Nutr, 2016). It was oral, small and short, and it is the kind of signal we build on rather than a result we can promise.

For the intravenous route the picture is thinner. A 2026 PRISMA-guided systematic review of 113 studies, including 33 human intervention trials, found that oral precursors reliably raise NAD-related metabolites while effects on functional and metabolic outcomes were heterogeneous and often null, and it identified no eligible outcome trial of intravenous NAD+ for aging or wellness indications at all (Gallagher et al., Ageing Res Rev, 2026).

What the evidence does not show: that intravenous NAD+ improves fatigue, cognition or aging markers in a controlled trial; the human trial data for the infusion itself are sparse.

Safety at the rates we use is good in our experience, and the side effects are rate-dependent: chest tightness, nausea, flushing, abdominal cramping and muscle cramping when the drip runs too fast, all of which settle when it is slowed. That is why a nurse is present, pulse and blood pressure are recorded, and the first session starts lower than the later ones.

Where we use it

How it fits your program

NAD+ is a supporting module in the fatigue-led programs. In Post-COVID and chronic fatigue our physicians schedule it alongside hyperbaric oxygen therapy, high-dose vitamin drips with B vitamins and glutathione, and where the laboratory supports it methylene blue infusions, which act on the same electron transport chain from a different side. In the Lyme program it follows the antimicrobial and hyperthermia block, when energy reserves are lowest. Immune therapy with thymus peptides and ozone therapy are added from the same plan, and the detoxification therapies frame the block.

We measure before the first session and again in week two: the fatigue questionnaire, the metabolic markers and, in the longevity program, the functional tests from the work-up. The discharge letter, written in English for your physician at home, states which components continue orally and what the follow-up plan is. The pattern of a stay from admission to discharge is described on how a stay runs.

Costs

Costs and billing

You receive a written, itemized cost overview after a physician has read your findings and before anything is booked. Costs are a package price plus individual add-ons, and a deposit is paid before admission; NAD+ infusions appear as one block within the infusion therapies, priced per session. Treatment is self-pay, and the invoice is itemized in English with diagnoses and procedure descriptions for out-of-network review. Details are on costs and insurance; the path from first email to arrival from Munich Airport is on information for international patients.

Questions

Questions patients ask

Does NAD+ infusion work better than NAD+ capsules?

Nobody has shown that in a trial. Oral precursors such as nicotinamide riboside raise blood NAD+ in randomized studies. A pilot study of a six-hour NAD+ infusion found the molecule cleared from plasma within the first two hours, so the infusion delivers it, but a head-to-head comparison of outcomes does not exist. We use the infusion inside an inpatient plan, with oral support afterwards.

Why does the infusion take so long?

NAD+ given quickly causes chest tightness, nausea, flushing and muscle cramping in many people. Run slowly over two to four hours, with the rate raised step by step, most patients feel little beyond a mild warmth. If a symptom appears, the nurse slows the drip and it usually settles within minutes. The length is the safety measure.

Who should not have NAD+ infusions?

We do not give the infusion in pregnancy or while breastfeeding, in unstable heart disease or uncontrolled high blood pressure, or during active chemotherapy without the agreement of our oncology team, because the metabolic effects in tumors are not well characterized. Patients with kidney impairment receive a lower rate. Every exclusion is checked in the work-up before the first session.

How many sessions are usual, and what happens after?

Three to five infusions across a two- to three-week stay is the usual pattern, spaced so they do not fall on the same day as other long infusions. Before the first session and in the second week we repeat the fatigue questionnaire and the metabolic markers from the work-up. The discharge letter states whether an oral precursor continues at home.

How much does NAD+ therapy cost?

NAD+ infusions appear as a therapy block in the written, itemized cost overview that you receive after a physician has read your findings. The written cost overview shows the package price plus the individual add-ons your plan needs. Treatment is self-pay; the invoice is written in English for out-of-network review.

Write to the International Office with a short history; it requests your findings afterwards. A physician reads them before the video consultation and tells you whether NAD+ belongs in your plan.

References

  1. A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6 hour intravenous infusion of NAD+. Front Aging Neurosci 2019. PMID 31572171
  2. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun 2018. PMID 29599478
  3. Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review. Am J Physiol Endocrinol Metab 2024. PMID 37971292
  4. Effect of coenzyme Q10 plus nicotinamide adenine dinucleotide supplementation on maximum heart rate after exercise testing in chronic fatigue syndrome: a randomized, controlled, double-blind trial. Clin Nutr 2016. PMID 26212172
  5. NAD+ supplementation for anti-aging and wellness: a PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Res Rev 2026. PMID 41655607

Send a free inquiry

The initial inquiry is free of charge. The International Office reviews your message and your case directly and gets back to you.

Hours
Mon–Thu 08:00–17:00, Fri 08:00–14:00 German time (CET/CEST); in the US Mon–Thu 2–11 a.m. ET, Fri 2–8 a.m. ET.

Munich Airport (MUC), about 60 minutes by car.

CallSend a free inquiry